Biopharmaceutical company developing vaccines and immuno-oncology therapies.
Dynavax Technologies Corporation is a pioneering biopharmaceutical company based in Emeryville, California, specializing in the development and commercialization of innovative vaccines within the United States. Established in 1996 and originally known as Double Helix Corporation, the company rebranded to Dynavax Technologies Corporation in September 1996 to reflect its evolving focus and commitment to advancing medical science.
At the core of Dynavax's portfolio is HEPLISAV-B, a hepatitis B vaccine designed to prevent infections caused by all known subtypes of the hepatitis B virus in individuals aged 18 years and older. This vaccine is marketed both in the United States and Europe, highlighting Dynavax's global reach and impact in combating infectious diseases.
In addition to its vaccine offerings, Dynavax Technologies manufactures and distributes CpG 1018, an innovative adjuvant used in the formulation of HEPLISAV-B. This proprietary adjuvant enhances the immune response to vaccines, thereby improving their efficacy and broadening their application in healthcare settings.
Dynavax Technologies Corporation collaborates extensively with industry leaders and institutions to bolster its research and development efforts. Notable partnerships include agreements with Valneva Scotland Limited, Serum Institute of India Pvt. Ltd., and a sublicense agreement with Merck, Sharp & Dohme Corp. These collaborations underscore Dynavax's strategic approach to advancing vaccine technologies and expanding its global presence in the biopharmaceutical industry.